- Report
- January 2022
- 200 Pages
Global
From €7151EUR$7,500USD£6,129GBP
- Report
- January 2022
- 60 Pages
Global
From €3766EUR$3,950USD£3,228GBP
- Report
- January 2022
- 60 Pages
Global
From €3766EUR$3,950USD£3,228GBP
- Report
- December 2022
- 118 Pages
Global
From €4291EUR$4,500USD£3,678GBP
- Report
- October 2022
- 80 Pages
Europe
From €3576EUR$3,750USD£3,065GBP
- Report
- September 2022
- 82 Pages
Turkey
From €3194EUR$3,350USD£2,738GBP
- Report
- March 2023
- 75 Pages
Spain
From €3194EUR$3,350USD£2,738GBP
- Report
- January 2023
- 173 Pages
Global
From €2384EUR$2,500USD£2,043GBP
- Report
- August 2022
Global
From €1135EUR$1,190USD£973GBP
- Report
- August 2022
United States
From €1850EUR$1,940USD£1,585GBP
- Report
- August 2021
Europe
From €3261EUR$3,420USD£2,795GBP
- Report
- August 2021
Global
From €3804EUR$3,990USD£3,261GBP
- Report
- February 2021
Global
From €2822EUR$2,960USD£2,419GBP
- Report
- November 2020
- 46 Pages
Global
From €3809EUR$3,995USD£3,265GBP
- Drug Pipelines
- July 2020
- 1191 Pages
Global
From €2384EUR$2,500USD£2,043GBP
- Drug Pipelines
- December 2019
- 84 Pages
Global
From €3337EUR$3,500USD£2,860GBP
- Drug Pipelines
- May 2018
- 79 Pages
Global
From €1907EUR$2,000USD£1,634GBP
- Report
- October 2021
- 41 Pages
United States
From €973EUR$1,020USD£834GBP
- Report
- April 2018
United States
From €7623EUR$7,995USD£6,534GBP
- Drug Pipelines
- August 2018
- 610 Pages
Global
From €20977EUR$22,000USD£17,979GBP
The Rheumatoid Arthritis Drug market is a subset of the Immune Disorders Drugs market. It is composed of drugs used to treat rheumatoid arthritis, an autoimmune disorder that causes inflammation of the joints. These drugs are used to reduce inflammation, pain, and stiffness, as well as to prevent joint damage. They can be divided into two categories: disease-modifying antirheumatic drugs (DMARDs) and biologic response modifiers (BRMs). DMARDs are used to slow the progression of the disease, while BRMs are used to reduce inflammation and pain.
The Rheumatoid Arthritis Drug market is highly competitive, with many companies offering a variety of treatments. Some of the major players in the market include AbbVie, Amgen, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, and Roche. Show Less Read more